High-Level Overview
Nest Genomics (YC W22) is a health technology company building a lab-agnostic software platform that integrates genomic information into clinical workflows, enabling providers, patients, and navigators to deliver actionable genetic insights at the point of care.[1][2][5][6] It serves healthcare organizations, providers, and patients by streamlining patient identification, risk assessment, test ordering, consent, counseling, EMR-integrated decision support, and long-term care management, addressing the challenge of making genetics part of everyday health to advance personalized medicine and improve outcomes.[2][4][6] With an estimated annual revenue of $588.8k, 16 employees, and partnerships like athenahealth and Genome Medical, the company shows steady operations in the SaaS healthcare space, backed by Y Combinator and total funding around $8.5M-$9M.[1][2][3]
Origin Story
Nest Genomics was founded in 2022 by repeat entrepreneurs Moran Snir (CEO) and Guy Snir (COO), both with deep genomics experience from co-founding Clear Genetics (YC W17, acquired by Invitae), where they built tools like the GIA chatbot to integrate genetics into routine care.[4][5][6] Guy Snir previously led SaaS teams at Invitae, held product roles at Twitter, SnappyTV, Google/Motorola, and holds degrees from Duke and Tel-Aviv University.[6] The idea emerged from their prior success in genomic software, evolving into a comprehensive platform for scaling genomic programs amid growing demand for personalized medicine; early traction includes YC Winter 2022 backing, New York base (with Delaware HQ), and integrations with major health platforms.[1][3][5][6]
Core Differentiators
- Comprehensive, Lab-Agnostic Platform: End-to-end solution covering triage, consent, counseling, EMR-integrated decision support, and continuum-of-care management, unlike fragmented tools.[2][4][6]
- Engineering-Led, User-Centered Design: YC-backed team builds evidence-based, beautiful products prioritizing provider workflows and scalability, drawing from prior exits like Clear Genetics.[5][6]
- Seamless Integrations and Partnerships: Embedded in systems like athenahealth's Marketplace and collaborations with Genome Medical, enabling real-world genomic program launches.[2]
- Focus on Actionable Insights: Delivers genomic data directly into clinical care, supporting patient identification, risk assessment, and personalized outcomes without lab dependencies.[1][4]
Role in the Broader Tech Landscape
Nest Genomics rides the personalized medicine trend, where genomics shifts from specialty to routine care amid falling sequencing costs and regulatory pushes for precision health.[2][5] Timing aligns with post-pandemic healthcare digitization, EMR adoption, and demand for scalable genetic screening in primary care, fueled by market forces like aging populations and chronic disease prevalence.[1][6] It influences the ecosystem by democratizing genomic access—bridging patients, providers, and labs—much like prior tools from its founders, accelerating adoption in a $100B+ genomics market while competing with firms like Revv and Daloopa.[1][4]
Quick Take & Future Outlook
Nest Genomics is positioned for expansion as genomic integration becomes standard in clinical workflows, potentially scaling via more EMR partnerships and enterprise deals. Trends like AI-driven insights and value-based care will shape its path, with its repeat-founder pedigree enabling rapid iteration toward larger genomic programs. Its influence may grow through acquisitions or IPOs in health tech, evolving from YC startup to key enabler of everyday genetics—building on its Clear Genetics roots to redefine personalized health.
